Financings in Brief: Urologix
This article was originally published in The Gray Sheet
Executive Summary
Urologix: Files with SEC for a proposed secondary offering of 1.5 mil. shares of common stock. The Minneapolis maker of minimally invasive devices for treatment of urological diseases received FDA approval Aug. 22 for its Targis microwave therapy device for treating benign prostatic hyperplasia ("The Gray Sheet" Sept. 1, p. 4), and plans to use proceeds from the offering to fund sales and marketing efforts, "to expand manufacturing capacity, and for working capital and other general corporate purposes," the firm says. Underwriters BT Alex. Brown, Dain Bosworth and PaineWebber hold an over-allotment option for 225,000 additional shares...